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Contact Information 
 
Welcome  
Hepatitis B is a serious disease caused by the hepatitis B virus (HBV), which can be transmitted from an 
infected mother to her infant at birth. The Iowa Department of Public Health, Perinatal Hepatitis B 
Program works to prevent transmission of hepatitis B infection from mothers to infants by conducting 
parent and health care provider education, case management of mothers and babies, distribution of 
hepatitis B vaccine and hepatitis B immune globulin (HBIG), and laboratory testing. 
 
Contact Information 
State Perinatal Hepatitis B 
Prevention Program Coordinator  
Shelly Jensen, RN, BSN  
Perinatal Hepatitis B Prevention Program 
Bureau of Immunization & TB 
Iowa Department of Public Health  
321 East 12th Street 
Des Moines, IA  50319 
Shelly.Jensen@idph.iowa.gov 
 
Local: (515) 281-4938 
Long Distance: (800) 831-6293, Ext 2 
Fax: (800) 831-6292 
 
Iowa Immunization Program (800) 831-6293 
http://idph.iowa.gov/immtb/immunization 
https://idph.iowa.gov/immtb/immunization/perinatal-hepb 
 
State Hygienic Lab  http://www.shl.uiowa.edu/ 
 
IDPH Center for Acute Disease 
Epidemiology (CADE) 
Local Phone: (515) 242-5935  
Long-distance Phone: (800) 362-2736 
https://idph.iowa.gov/CADE 
 
  
 5 
 
Statement of Iowa Law and HIPAA 
 
HIPAA  
Parental Refusal  
 
Iowa Code Chapter 139A and 641 Iowa Administrative Code Chapter 1 
The Iowa Department of Public Health (IDPH), local boards of health, and local health departments are 
authorized to access medical records and other information of patients infected or suspected to be 
infected with a reportable disease. Iowa Administrative Code clearly outlines all reportable diseases, 
conditions and investigation methods for reportable diseases such as hepatitis B. Iowa law further 
requires health care providers and laboratories to assist in public health disease investigations: “The 
health care provider or public, private, or hospital clinical laboratory attending a person infected with a 
reportable disease shall report the case to the department. A health care provider or public, private, or 
hospital clinical laboratory who files such a report which identifies a person infected with a reportable 
disease shall assist in the investigation by the department, a local board, or a local department.” A 
health care provider or public, private, or hospital clinical laboratory shall provide the department, local 
board, or local department with all information reasonably necessary to conduct an investigation 
pursuant to this chapter upon request of the department, local board, or local department.  
 
 Chapter 139A Communicable and Infectious Diseases and Poisonings 
 Iowa Administrative Code 641- Reporting of reportable communicable and infectious diseases 
 
HIPAA 
As a result of the state law requirements listed above, the HIPAA privacy rule expressly permits covered 
entities (including providers and clinics) to report disease information and participate in a public health 
disease investigation without obtaining consent or authorization from the patient. (45 CFR 160.203(c); 
45 CFR 164.512(a)(1); 45 CFR 164.512(b)(1)(i))  
 
For this reason, IDPH and local public health authorities conducting a hepatitis B investigation are 
authorized to access patient specific information directly from providers, clinics, and hospitals without 
obtaining a consent or release from the patient. IDPH and local public health authorities may conduct all 
activities outlined in the IDPH EPI Manual, including case investigation of infants born to HBsAg-positive 
women, without obtaining consent or authorization from the patient.   
 
For full text of IDPH’s HIPAA statement visit: https://idph.iowa.gov/hipaa-statement.  
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Parent Refusal 
Parents are not legally required to assist in a case investigation without the issuance of a subpoena by 
the department. There have been instances when a parent has refused to provide information to the 
investigating nurse regarding the HBsAg and/or immunization status of household contacts.   
 
If this occurs while investigating a case, reiterate to the parent the reason for collecting the information. 
Assure them of patient confidentiality, and inform them you will seek the rest of the information 
needed to complete the IDPH Perinatal Hepatitis B Carrier Follow-up Report form directly from the 
mother's and baby's health care providers.   
 
If they continue to refuse to provide information, document the discussion on the Perinatal Hepatitis B 
Carrier Follow-up Report form and/or in IDSS (Iowa Disease Surveillance System) and notify the Perinatal 
Hepatitis B Prevention Program Coordinator not to contact the parent. 
 
As stated above, parents are not required to assist in the case investigation and should not be pressured 
to gain information on the status of household members. Adequate information regarding the HBsAg-
positive mother and resulting child is obtainable through medical providers.   
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Hepatitis B Vaccine and HBIG  
 
Hepatitis B Vaccine  
Hepatitis B Immune Globulin (HBIG) 
Availability of Hepatitis B Vaccine and HBIG 
 
Hepatitis B Vaccine 
o HBsAg is the antigen used for hepatitis B vaccination.  
o Since March 2000, hepatitis B vaccines produced for distribution in the United States do not 
contain thimerosal as a preservative or contain only a trace amount (<1.0 mcg mercury/mL) 
resulting from the manufacturing process.  
o Hepatitis B vaccine is available as a single-antigen formulation and in combination with other 
vaccines.  
o Two single-antigen hepatitis B vaccines are licensed for use in infants and young children in the 
United States: Recombivax HB® (Merck) and Engerix-B® (GlaxoSmithKline).  
o Only single antigen vaccine should be used for the birth dose. 
o Pediarix® (GlaxoSmithKline) is the only licensed combination hepatitis B vaccine available for 
vaccination of infants and young children. This vaccine may be used to complete the remaining 
doses of the hepatitis B vaccine series.    
 
Information regarding hepatitis B vaccine can be found on page 158 of Appendix 6. 
 
Hepatitis B Immune Globulin (HBIG) 
HBIG provides passively acquired hepatitis B surface antibody (anti-HBs) and temporary protection (e.g., 
3-6 months) when administered in standard doses. HBIG is used as an adjunct to hepatitis B vaccine for 
post-exposure immunoprophylaxis to prevent HBV infection. HBIG can augment protection until a 
response to vaccination is attained. HBIG is prepared from the plasma of donors with high 
concentrations of anti-HBs. HBIG is commercially available in the United States and does not contain 
thimerosal.  
 
Availability of Hepatitis B Vaccine and HBIG 
The VFC program will support requests for 4 doses of hepatitis B vaccine for routine vaccination of 
infants when using combination vaccines. However, the Iowa VFC Program asks providers to consider 
using single antigen hepatitis B vaccine when appropriate. If a client is unable to pay for the hepatitis B 
vaccine or HBIG* contact:  
Shelly Jensen, RN, BSN 
Shelly.Jensen@idph.iowa.gov 
(800) 831-6293, ext. 2 
 
*IDPH does not maintain HBIG in inventory. It is vital the Immunization Program receive notification as 
soon as the need is identified so doses may be ordered directly from the manufacturer.   
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HBsAg Testing 
 
HBsAg and Infection 
SHL (State Hygienic Lab) 
Reporting of HBsAg Positive Tests 
Action for LPHA 
 
HBsAg (hepatitis B surface antigen) is the confirmatory test to indicate if an individual is currently 
infected with the hepatitis B virus  
 
HBsAg and Infection 
The presence of a confirmed HBsAg positive result is indicative of current HBV infection, either acute or 
chronic. All HBsAg positive persons should be considered infectious. If a person was vaccinated against 
hepatitis B within the past 18 days, they may have a false-positive HBsAg result due to circulating 
antigen in their blood from the vaccine. In newly infected persons, HBsAg is the only serologic marker 
detected during the first 3-5 weeks after infection, and it persists for variable periods at very low levels. 
The average time from exposure to detection of HBsAg is 30 days (range: 6-60 days). 
 
SHL (State Hygienic Lab) 
Serological specimens may be submitted to the State Hygienic Laboratory (SHL) for any sexual or 
household contact (including children) of an HBsAg-positive pregnant woman who is unable to pay for 
the testing. Those who wish to submit specimens to SHL should contact the State Perinatal Hepatitis B 
Prevention Program Coordinator for instructions and approval. 
 
Reporting of HBsAg Positive Tests  
If a woman has a positive HBsAg test, the case must be reported to the Iowa Department of Public 
Health, Center for Acute Disease Epidemiology (CADE) within 3 days of diagnosis per Iowa 
Administrative Code 614 Chapter 1. The form for reporting a hepatitis B case is located in the CADE EPI 
Manual. The case may be reported through any of the following:  
o Iowa Disease Surveillance System (IDSS) 
o Phone:(800) 362-2736 
o Secure fax: (515) 281-5698 or 
o Mail to: 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Action for LPHAs 
1. If the lab slip comes directly from a provider or lab, confirm the case was reported to IDPH.   
2. Complete Section I of the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report” form. 
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Hepatitis B Serology 
 
Hepatitis B Laboratory Nomenclature 
HBsAg: Hepatitis B surface antigen is a marker of infectivity. Its presence indicates either acute or chronic HBV infection. 
anti-HBs: Antibody to hepatitis B surface antigen is a marker of immunity. Its presence indicates an immune response to 
HBV infection, an immune response to vaccination, or the presence of passively acquired antibody. (It is also 
known as HBsAb, but this abbreviation is best avoided since it is often confused with abbreviations such as 
HBsAg.) 
anti-HBc 
(total):  
Antibody to hepatitis B core antigen is a nonspecific marker of acute, chronic, or resolved HBV infection. It is not 
a marker of vaccine-induced immunity. It may be used in pre-vaccination testing to determine previous exposure 
to HBV infection. (It is also known as HBcAb, but this abbreviation is best avoided since it is often confused with 
other abbreviations.) 
IgM anti-HBc: IgM antibody subclass of anti-HBc. Positivity indicates recent infection with HBV (<6 mos). Its presence indicates 
acute infection. 
HBeAg: Hepatitis B "e" antigen is a marker of a high degree of HBV infectivity, and it correlates with a high level of HBV 
replication. It is primarily used to help determine the clinical management of patients with chronic HBV infection. 
Anti-HBe: Antibody to hepatitis B "e" antigen may be present in an infected or immune person. In persons with chronic 
HBV infection, its presence suggests a low viral titer and a low degree of infectivity. 
HBV-DNA: HBV Deoxyribonucleic acid is a marker of viral replication. It correlates well with infectivity. It is used to assess 
and monitor the treatment of patients with chronic HBV infection. 
 
Interpretation of Common Hepatitis B Panel Results 
Tests Results Interpretation Vaccinate? 
HBsAg 
anti-HBc 
anti-HBs 
negative 
negative 
negative 
susceptible vaccinate if indicated 
HBsAg 
anti-HBc 
anti-HBs 
negative 
negative 
positive with 
>10mIU/mL* 
immune due to 
vaccination 
no vaccination necessary 
HBsAg 
anti-HBc 
anti-HBs 
negative 
positive 
positive 
immune due to natural 
infection 
no vaccination necessary 
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs 
positive 
positive 
positive 
negative 
acutely infected no vaccination necessary 
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs 
positive 
positive 
negative 
negative 
chronically infected no vaccination necessary 
(may need treatment) 
HBsAg 
anti-HBc 
anti-HBs 
negative 
positive 
negative 
four interpretations 
possible† 
use clinical judgment 
* Post-vaccination testing, when recommended, should be performed 1–2 months after the last dose of vaccine. Infants born to HBsAg-positive mothers should be tested for 
HBsAg and anti-HBs after completion of at least 3 doses of a licensed hepatitis B vaccination series, at age 9-12 moths (generally at the next well child visit.) 
†1. Passive transfer after the hepatitis B immune globulin 
 2. May be distantly immune, but the test may not be sensitive enough to detect a very low level of anti-HBs in serum 
 3. May be susceptible with a false positive anti-HBc 
 4. May be chronically infected and have an undetectable level of HBsAg present in the serum 
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Screening of Pregnant Women 
 
Country of Origin 
Early Testing 
Transfer of Test Results  
Admission Testing 
HBsAg Positive Mother 
HBsAg Status of Mother Unknown 
HBsAg Negative Mother 
Action for LPHA 
 
Timely identification of HBsAg positive pregnant women provides the opportunity to educate and 
initiate appropriate case management to prevent further transmission of the virus to the neonate and 
other susceptible household contacts. 
 
Country of Origin 
Residents and descendants of certain countries and regions of the world are more prone to HBsAg 
infection as the disease was, or currently is, endemic (2% or more of the population is infected). Clients 
from the following countries/regions may have an increased risk for HBsAg infection:   
 
Afghanistan, Africa, rural Alaska, Albania, Bangladesh, Bosnia and Herzegovina, Bulgaria, Cambodia, 
China, Eastern Europe, Haiti, Hawaii, India, Indonesia, Iran, Iraq, Korea, Laos, Malaysia, the Middle East, 
Myanmar, Pakistan, the Pacific Islands, Philippines, Romania, the former Soviet Union, South America’s 
Amazon Basin, Sri Lanka, Syria, Taiwan, Thailand, or Vietnam.  
 
Early Testing 
All pregnant women should be tested routinely for HBsAg during an early prenatal visit (e.g., first 
trimester) in each pregnancy, even if they were previously vaccinated, tested, or HBsAg positive. 
 
In special situations, an additional HBsAg test may be ordered during the third trimester. This should be 
considered if the patient develops symptoms, is exposed to HBV, or engages in high-risk behavior (e.g., 
having had more than one sex partner in the previous 6 months, having an HBsAg positive sex partner, 
evaluation or treatment for a sexually transmitted disease [STD], or recent/current injection-drug use). 
 
Transfer of Test Results 
Pregnant women who are HBsAg positive should have a copy of the original laboratory report indicating 
HBsAg status provided to the hospital or birthing facility where delivery is planned and to the healthcare 
provider who will care for the newborn. 
Pregnant women who are HBsAg positive should also be referred to the state Perinatal Hepatitis B 
Prevention Coordinator for overall case management.  
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Admission Testing 
Women not screened prenatally, those who engage in behaviors putting them at high risk for infection 
(see high-risk behaviors on the previous page) and those with clinical hepatitis should be tested at the 
time of admission for delivery. 
 
Women admitted for delivery without documentation of HBsAg test results should have blood drawn 
and tested as soon as possible after admission. While test results are pending, all infants born to women 
without documentation of HBsAg test results should receive the first dose of single-antigen hepatitis B 
vaccine within 12 hours of birth. 
 
HBsAg Positive Mother 
If the mother is HBsAg positive and the child weighs 2,000 grams (4.4 lbs.) or more at birth:  
o Give infant HBIG and hepatitis B vaccine within 12 hours of birth 
o Continue vaccine series on an accelerated schedule beginning at 1-2 months of age and 
completing the 3 dose series at 6 months of age (the final dose in the series should not be 
administered before age 24 weeks). 
o Check quantitative anti-HBs and HBsAg 1-2 months after completion of vaccine series at 9-12 
months of age. Testing should not be performed before age 9 months to avoid detection of 
passive anti-HBs from HBIG administered at birth.  
 
If the mother is determined to be HBsAg positive and the child weighs less than 2,000 grams (4.4 lbs.) at 
birth:  
o Give infant HBIG and hepatitis B vaccine within 12 hours of birth 
o Continue vaccine series on an accelerated schedule beginning at 1-2 months of age and 
complete the 4 dose series at 6 months of age (the final dose in the series should not be 
administered before age 24 weeks).  
o Due to potentially reduced immunogenicity of the birth dose in these infants do not count 
birth dose as part of the typical 3-dose vaccine series. Instead, immunize with 4 total doses of 
vaccine.  
o Check quantitative anti-HBs and HBsAg 1-2 months after completion of vaccine series at 9-12 
months of age. Testing should not be performed before age 9 months to avoid detection of 
passive anti-HBs from HBIG administered at birth.  
 
HBsAg Status of Mother Unknown 
Infants born to women with unavailable HBsAg testing results, but with evidence suggesting 
maternal HBV infection exists (e.g., presence of HBV DNA, HBeAg-positive, or mother known to be 
chronically infected with HBV) should be managed as if born to an HBsAg positive mother. The infant 
should receive both hepatitis B vaccine and HBIG within 12 hours of birth. The hepatitis B vaccine 
series should be completed according to the recommended schedule for infants born to HBsAg 
positive mothers and post vaccination serology (quantitative anti-HBs and HBsAg) should be 
performed at age 9-12 months (at least 1-2 months following completion of hepatitis B vaccine 
series).  
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If it is not possible to determine the mother’s HBsAg status (e.g., when a parent or person with 
lawful custody safely surrenders an infant confidentially shortly after birth) the vaccine series should 
be completed according to the recommended schedule for infants born to HBsAg positive mothers. 
The final dose in the series should not be administered before age 24 weeks. These infants should 
receive post vaccination serology (quantitative anti-HBs and HBsAg) at age 9-12 months.  
 
If the mother’s HBsAg status is unknown and the child weighs 2,000 grams (4.4 lbs.) or more at 
birth: 
o Test mother for HBsAg immediately after admission.  
o While maternal HBsAg results are pending, give infant hepatitis B vaccine within 12 hours 
of birth. 
o Give infant HBIG as soon as possible, but no later than age 7 days if mother tests HBsAg 
positive. If the mother’s HBsAg status remains unknown at the time of discharge it may be 
appropriate to provide HBIG to the child prior to release from the hospital. Efforts should be 
made to determine HBsAg status prior to discharge, but in the absence of this information 
and faced with a situation where you are unsure the child will receive appropriate follow-up, 
providing HBIG may be appropriate.  
o Continue vaccine series beginning at 1-2 months of age according to the recommended 
schedule based on mother’s HBsAg status. The final dose in the series should not be 
administered before age 24 weeks.  
o Check quantitative anti-HBs and HBsAg after completion of vaccine series at 9-12 months of 
age if mother is determined positive for HBsAg or if her status remains unknown. 
 
If the mother’s HBsAg status is unknown and the child weighs less than 2,000 grams (4.4 lbs.) at 
birth:  
o Test mother for HBsAg immediately after admission. 
o Give infant hepatitis B vaccine within 12 hours of birth. 
o Give infant HBIG if mother tests HBsAg positive OR if mother’s HBsAg result is not 
available within 12 hours of birth.  
o Do not count birth dose as part of vaccine series. Immunize with 4 doses of vaccine.  
o Continue vaccine series beginning at 1-2 months of age according to the recommended 
schedule based on mother’s HBsAg status (the final dose in the series should not be 
administered before age 24 weeks).  
o Check quantitative anti-HBs and HBsAg after completion of vaccine series at 9-12 months of 
age if mother is determined positive for HBsAg or if her status remains unknown.  
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HBsAg Negative Mother 
If the mother is determined to be HBsAg negative, the infant weighing 2,000 grams or more should 
receive the birth dose of hepatitis B vaccine within 24 hours of birth. The series should be completed 
according to the ACIP Recommended Childhood and Adolescent Immunization Schedule (birth, 1-2, and 
6-18 months). 
 
For infants born weighing less than 2,000 grams, the birth dose of hepatitis B vaccine should be 
deferred until hospital discharge or 1 month of age (even if weight is still less than 2,000 grams). For 
these infants, the series should be completed per the ACIP recommended immunization schedule. 
Infants weighing less than 2,000 grams at birth have a decreased response to HepB vaccine 
administered before age 1 month.  
 
Action for LPHAs 
1. Confirm with the women’s provider a copy of the original laboratory report indicating her HBsAg 
status was provided to the hospital where delivery is planned. 
2. Contact hospital notifying them of mother’s plans for delivery and status.  
3. Contact the child’s health-care provider and discuss vaccination and HBIG as well as serology.  
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HBsAg Positive Pregnant Women 
 
HBV Education 
Action for LPHAs 
 
HBV Education 
HBsAg positive pregnant women should receive information on hepatitis B that includes:  
o Modes of transmission and how to prevent transmission  
o Perinatal concerns (e.g., there is no contraindication for infants of HBsAg positive mothers to be 
breast fed beginning immediately after birth. Although HBsAg can be detected in breast milk, 
there is no evidence that HBV can be transmitted by breastfeeding). 
o Prevention of HBV transmission to contacts, including the importance of post-exposure 
prophylaxis for the newborn, other household contacts, sexual partners, and needle-sharing 
contacts 
o Substance abuse treatment, if appropriate  
o Medical evaluation and possible treatment of chronic hepatitis  
 
Action for LPHAs 
Contact the woman and provide the following information:  
1. How you acquired her name (e.g., hepatitis B is a reportable disease in the state of Iowa and 
the lab and her provider are required to report the case). 
2. Explain your role and discuss what services you will provide to her and household contacts 
(case management, notification of providers/birth hospital or center, immunization services for 
eligible contacts, and testing for hepatitis B status). 
3. Explain what information you will be collecting while her case is “open.” Collect the pertinent 
information for the case (delivery plans and household contact information). 
4. Provide her with the Hepatitis B Brochure.  
5. Discuss the importance of the baby completing the vaccine series by six months of age (an 
infected unprotected baby has a 90% chance of becoming a chronic carrier) and of post-
vaccination serology. 
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Intervention for Infants  
Born to HBsAg+ Mothers  
 
Infants weighing 2,000 grams or more at birth 
Infants weighing less than 2,000 grams at birth 
Extended intervals between doses 
Pediarix 
Action for LPHAs 
 
Infants Weighing 2,000 Grams or More at Birth 
All infants born to HBsAg positive women should receive single-antigen hepatitis B vaccine (birth dose) 
and HBIG within 12 hours of birth, administered at different injection sites.  
 
Hepatitis B Dose Timing 
1 Birth dose  
2 4 weeks from dose 1 
3 
8 weeks from dose 2 AND 16 weeks from dose 1 
AND the infant is 6 months of age (minimum age 24 
weeks) 
 
For information on combination vaccine (Pediarix) see page 162 of Pink Book. 
 
Infants Weighing Less Than 2,000 Grams at Birth 
Infants weighing less than 2,000 grams (4.4 lbs.) born to HBsAg positive mothers should receive single-
antigen hepatitis B vaccine (birth dose) and HBIG within 12 hours of birth, administered at different 
injection sites.   
 
For infants weighing less than 2,000 grams, the initial vaccine dose (birth dose) should not be counted 
as part of the vaccine series because of the potentially reduced immunogenicity of hepatitis B vaccine in 
these infants. Give 3 additional hepatitis B vaccine doses with single-antigen vaccine at ages 1, 2 to 3, 
and 6 months, or hepatitis B-containing combination vaccine (Pediarix) at ages 2, 4, and 6 months. A 
total of four doses of hepatitis B vaccine are recommended in this circumstance. 
 
Extended Intervals Between Doses 
All doses not violating the minimum intervals are valid. It is not necessary to restart the vaccine series if 
there is an extended interval between doses.  
 
The minimum interval between the first and second dose is 4 weeks. The minimum interval between the 
second and third dose is 8 weeks and 16 weeks from the first dose, as long as the third dose is given 
after 6 months of age (see chart above).  
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Pediarix 
Pediarix (GSK) is a combination vaccine containing DTaP, hepatitis B, and IPV. Typically, Pediarix is given 
at 2, 4 and 6 months of age. When giving Pediarix after a birth dose of hepatitis B, the infant will receive 
a total of 4 doses of hepatitis B vaccine. Four doses of hepatitis B vaccine is permissible when using 
combination vaccines.   
 
Serologic testing following the Pediarix series is performed at least 1-2 months after the last dose of 
vaccine (typically given at 6 months of age). Testing should be performed at age 9-12 months. Testing 
should not be done prior to 9 months of age to avoid detection of the anti-HBs from HBIG administered 
at birth. For more serology information see the section titled “Post-Vaccination Serology.” 
Action for LPHAs 
1. Contact the birth hospital to complete the infant’s information and HBIG/vaccination status in 
Section II of the “Perinatal Hepatitis B Carrier Follow-up Report” form (Appendix 1). 
2. Contact the infant’s provider and give them the hepatitis B vaccine and HBIG information. Stress 
the importance of adhering to the accelerated schedule (3rd dose at 6 months) and post-
vaccination serology at 9-12 months of age. 
3. Update IDPH Perinatal Hepatitis B Prevention Coordinator of birth.  
4. Follow the infant through the vaccine series and document vaccination dates.    
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Post-Vaccination Serology 
 
Post-Vaccination Serology after the Initial Series 
Post-Vaccination Serology more than two-years after completion  
Test Results 
Action for LPHAs 
 
Post-vaccination serology for infants born to HBsAg positive mothers is the method of confirming 
protection from HBV. Post-vaccination serology is a key component to case management of the child. 
 
Post-Vaccination Serology after the Initial Series  
Post-vaccination testing for HBsAg and quantitative anti-HBs should be performed no sooner than 1-2 
months following completion of the hepatitis B vaccine series at age 9-12 months.  
 
It is very important to request the health care provider order quantitative anti-HBs, in addition to 
HBsAg. Without ordering a quantitative anti-HBs, there is no way to determine the antibody 
concentration and thus determine if the infant is protected (equal to or greater than 10 mIU/mL) or 
needs further doses of vaccine (less than 10 mIU/mL). See “Test Results” section below.  
 
Testing should not be performed before age 9 months to avoid detection of passive anti-HBs from HBIG 
administered at birth. Anti-HBc testing of infants is not recommended because passively acquired 
maternal anti-HBc might be detected in infants born to HBV-infected mothers to age 24 months.  
 
Use of single antigen hepatitis B vaccine or Pediarix: the final dose of hepatitis B containing vaccine 
should be given at age 6 months (no sooner than age 24 weeks), and serology should be drawn 3 
months later at the 9 month visit (at least 1-2 months following final dose of Hep B vaccine).  
 
Post-Vaccination Serology More Than Two Years After Completion of the HBV 
Series 
Post-vaccination serology done more than two years after the third dose of vaccine causes difficulty in 
interpreting the anti-HBs result because antibody levels begin to decrease in the blood below detectable 
levels, even though the child may still have active immunity.  
 
The child should receive one additional dose of vaccine (it is permissible to have 5 total doses in the 
series in this instance) and then have HBsAg and quantitative anti-HBs serology drawn 4-6 weeks after 
the dose to check immunity. This single dose is designed to “wake up” the immune response and then 
allow determination of protection.  
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Test Results 
HBsAg Negative Infants:  
o HBsAg-negative infants with anti-HBs levels equal to or greater than 10mIU/mL are protected 
and need no further medical management. 
 
o HBsAg-negative infants with anti-HBs levels less than 10mIU/mL should be revaccinated with a 
single dose of hepatitis B vaccine and receive post-vaccination serology 1-2 months later. Infants 
whose anti-HBs remain less than 10 mIU/mL following a single dose revaccination should receive 
2 additional doses of vaccine to complete the second series, followed by post-vaccination 
serology at 1-2 months following the final dose. Alternatively, based on clinical judgement or 
family preference, HBsAg negative infants with anti-HBs less than 10mIU/mL may be re-
vaccinated with a second complete 3 dose series, followed by post vaccination serology 
performed 1-2 months following this 2nd full series. Minimum intervals must be maintained 
when completing a second hepatitis B vaccine series.  
 
There is currently no data to support a benefit from administering additional hepatitis B vaccine doses 
to infants who have not attained anti-HBs >10mIU/mL following receipt of 2 complete hepatitis B 
vaccine series. These infants will be considered non-responders. HBsAg positive infants: should receive 
appropriate follow-up including periodic evaluation for liver function.   
 
Action for LPHAs 
1. Complete Section III of the “Perinatal Hepatitis B Carrier Follow-up Report” form (Appendix 1) 
upon post-vaccination serology and if necessary assist with referrals for HBsAg positive infant.  
2. Immediately notify IDPH Perinatal Hepatitis B Prevention Program Coordinator of HBsAg 
positive infant by calling (800) 831-6293, ext. 2. 
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Testing and Vaccination of  
Household and Sexual Contacts 
 
Transmission Reduction 
Pre and Post Vaccination Serological Testing and Vaccination  
Children at Risk 
Availability of Hepatitis B Vaccine 
Adult Vaccination and Vaccine Efficacy 
Action for LPHAs 
 
Transmission Reduction 
Sexual partners of HBsAg-positive persons should be counseled to use methods (e.g., condoms) to 
protect themselves from sexual exposure to infectious body fluids (e.g., semen or vaginal secretions) 
unless they have demonstrated immunity after vaccination (e.g., anti-HBs >10 mIU/mL) or previously 
infected (anti-HBc positive). 
 
Additionally, household contacts should be counseled to refrain from sharing household articles (e.g., 
toothbrushes, razors, nail clippers and files, or personal injection equipment) that could become 
contaminated with blood. 
 
Pre and Post Vaccination Serological Testing and Vaccination  
Screening is usually cost-effective, and should be considered in groups with a high risk of HBV infection 
such as men who have sex with men, injection-drug users, Alaska natives, Pacific Islanders, children of 
immigrants from endemic-disease countries, and family members of HBsAg-positive persons. 
Unvaccinated sexual partners, household contacts, and needle-sharing contacts should be tested for 
susceptibility to HBV infection and should receive the first dose of hepatitis B vaccine immediately after 
collection of the blood sample for serologic testing.  
Susceptible persons should complete the vaccine series using an age-appropriate vaccine dose and 
schedule. Persons who have begun the series in the past but did not complete it should now complete 
the full series. It is not necessary to restart the vaccine series if there is an extended interval between 
doses. 
 
Post-Vaccination serologic testing is also recommended for sexual partners of HBsAg-positive persons. 
When necessary, post-vaccination testing should be performed 1-2 months after completion of the 
vaccine series. 
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Children at Risk  
Children not infected at birth remain at risk from long-term interpersonal contact with their infected 
mothers. In one study, 38% of infants who were born to HBsAg positive mothers and who were not 
infected prenatally became infected by four years of age. 
 
In addition, children living with any chronically infected persons are at risk for becoming infected 
through percutaneous or mucosal exposures to blood or infectious body fluids (e.g., sharing a 
toothbrush, contact with exudates from dermatologic lesions, contact with HBsAg-contaminated 
surfaces). HBV transmission rates to susceptible household contacts of chronically infected persons have 
varied (range: 14%-60%).   
 
Availability of Hepatitis B Vaccine  
Hepatitis B vaccine provided by IDPH for contacts of HBsAg positive women is limited to children 
through the age of 18, primary sexual contacts, household contacts, and needle sharing partners who 
have no method of payment for vaccine. Vaccine may be ordered from IDPH on an as needed basis.   
 
IDPH makes available hepatitis B vaccine for children through 18 years of age who are living with an 
HBsAg positive woman and is provided at no cost to the client through the VFC Program. Agencies may 
administer hepatitis B vaccine to these children in the same manner they would to any other VFC 
eligible child and no special arrangements are necessary to obtain vaccine through IDPH. 
Agencies that identify a susceptible adult contact of an HBsAg positive woman are to contact the State 
Perinatal Hepatitis B Prevention Program Coordinator at 1-800-831-6293, ext. 2 to make arrangements 
to receive hepatitis B vaccine. The vaccine is made available to adult household contacts (persons over 
the age of 19) through non-federal funding.   
Clients immunized with state supplied vaccine must be entered and maintained in Iowa’s Immunization 
Registry Information System(IRIS). Vaccine administration recommendations and inventory 
requirements must be followed in accordance with current IDPH Immunization Program protocols.  
 
Action for LPHAs 
1. Obtain household contact information and complete pre-vaccination serologic testing of 
unvaccinated primary sexual partners and adult household contacts.   
2. Assure children living in the household are either vaccinated or currently receiving the hepatitis 
B vaccine series.  
3. As needed, make arrangements for vaccination and testing of susceptible contacts.  
4. Complete Section IV of the “Perinatal Hepatitis B Carrier Follow-up Report” form (Appendix 1).  
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Checklist for Follow-Up of Infants 
 
Checklist 
 
The following checklist outlines the steps to be carried out by local public health agencies for follow-up 
of infants born to women who are hepatitis B carriers. It is important to incorporate these steps into 
your work plan to ensure proper prophylaxis of infants and household contacts of women who are 
carriers of hepatitis B.   
 
Checklist 
Please see “HBsAg+ Exposed Infants Follow-Up Checklist”. 
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HBsAg+ Exposed  
Infants Follow-Up Checklist 
 
Prior to Delivery 
Following Delivery  
 
Prior to Delivery 
 Contact the mother’s provider. Make sure the provider is aware of the patient’s HBsAg positive 
lab result, the indicated immunoprophylaxis (HBIG) and hepatitis B vaccine for the infant, and 
provide the brochure “Hepatitis B Brochure.”  
 Contact the hospital or delivery center to ensure HBIG and hepatitis B vaccine will be on hand 
and the mother’s HBsAg status is noted in the prenatal record. 
 Prior to delivery, call, write, or make a home visit to the mother and provide perinatal hepatitis B 
educational materials (including the “Hepatitis B Brochure”).  
 Complete Section I of the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” with 
demographic information for the mother. Educate the mother on how to reduce risk of 
transmission of hepatitis B to her infant and household members. Update record in IDSS as 
necessary. 
 Complete Section IV on the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” Identify 
susceptible household contacts (children and sexual contacts) and encourage testing and 
vaccination. Document in mother’s hepatitis B case in IDSS under the follow-up tab and the notes 
section as needed.  
 
Following Delivery 
 Complete Section II of the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report”. Document in 
infant’s perinatal hepatitis B case in IDSS under the follow-up tab and update other tabs as 
needed. If infant is not found in IDSS, create a case or contact IDPH Perinatal Hepatitis B 
Prevention Coordinator.  
 Notify the infant’s pediatric provider of the mother’s positive HBsAg status and remind the 
provider the infant should receive the 2nd dose of vaccine at one to two months of age and the 
3rd dose of vaccine at 6 months of age (the final hepatitis B vaccine should not be administered 
prior to age 24 weeks) as well as post-vaccination serology between 9 and 12 months of age. 
Serology should not be drawn prior to 9 months of age and at least 1-2 months following the final 
dose of hepatitis B vaccine. Make follow-up calls or visits with the mother to make sure that her 
baby has gone in for his/her vaccinations and serology test. Document in the infant’s perinatal 
hepatitis B case in IDSS and update vaccinations under Section II of the “Perinatal Hepatitis B 
Carrier Follow-Up Report”.  
 
* The infant may receive an additional dose of hepatitis B vaccine depending on type of vaccine 
administered or if infant weighed less than 2,000 grams at birth.  
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 At 9-12 months of age, collect post-vaccination serology results. Be sure the provider tests for 
both HBsAg and quantitative Anti-HBs. Complete Section III of the IDPH “Perinatal Hepatitis B 
Carrier Follow-Up Report Form.” Document in the infant’s perinatal hepatitis B case in IDSS.  
 If the infant doesn’t develop an antibody response to the hepatitis B vaccine and remains 
negative for hepatitis B infection, call the infant’s medical provider and fax/send a request to 
revaccinate the infant with a single dose of hepatitis B vaccine and complete post-vaccination 
serologic testing 1-2 months later. Infants whose anti-HBs remain <10mlU/mL following this 
single dose revaccination should receive two additional doses of hepatitis B vaccine to complete 
the 2nd series followed by post-vaccination serologic testing 1-2 months following this final dose. 
Alternatively, the family and physician may choose to revaccinate with the entire 3 dose series 
followed by post vaccination serology.    
 Complete the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report” form with all hepatitis B 
vaccination dates and test results and fax/send to IDPH or send a notification through IDSS to the 
statewide Perinatal Hepatitis B Coordinator-Shelly Jensen.  
 
Periodically update the Perinatal Hepatitis B Prevention Program with your progress at the following 
intervals: 
o After Section I is completed for mom and household contacts (Section IV) 
o After contacts have completed the first dose in the series, or had serology to indicate no vaccine 
is needed (Section IV). 
o After the baby is born and HBIG and birth dose of hepatitis B vaccine have been given. 
o Upon completion of each dose of vaccine in the series for newborn and contacts. 
o Upon completion of serology for infant and closing of case.  
 
Please send results through any of the following:  
o IDSS via the notification option to Shelly Jensen 
o Email: Shelly.Jensen@idph.iowa.gov 
o Fax: (800) 831-6292) or 
o Mail to: 
Lucas State Office Building, IDPH Immunization Program 
Attn: Shelly Jensen 
321 E. 12th St. 
Des Moines, IA 50319-0075 
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Letter to Mothers 
 
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Dear _________________:  
 
Congratulations on the birth of your new baby NAME! Your baby received HBIG (Hepatitis B Immune 
Globulin) and the first dose of hepatitis B vaccine on DATE at HOSPITAL NAME. It is very important your 
child receive the second and third doses of hepatitis B vaccine on time.   
 
This letter is to remind you the second hepatitis B vaccination is due no later than two months of age. 
The third hepatitis B vaccination is due at six months of age.   
 
Your baby’s health care provider will test your child’s blood for the hepatitis B virus between nine 
months and one year of age. After the blood work is completed and if your baby needs no further doses 
of hepatitis B vaccine, we will close your case.   
 
I have enclosed information regarding hepatitis B. If you have any questions, you may contact the 
Perinatal Hepatitis B Prevention Program at YOUR PHONE HERE. Thank you for your cooperation.   
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
 
Enc. 
Note:  Please bring this letter with you to your baby’s next doctor appointment for his/her second 
Hepatitis B shot. 
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Letter to Mother’s Provider 
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Dear _________________:  
 
 
The Iowa Department of Public Health received a report for NAME AND DOB indicating she is hepatitis B 
surface antigen (HBsAg) positive and pregnant.   
 
Preventing perinatal transmission of hepatitis B through timely prophylaxis is a critical safeguard for the 
newborn. The CDC recently published a MMWR titled “Prevention of Hepatitis B Virus Infection in the 
United States: Recommendations of the Advisory Committee on Immunization Practices” January 2018. 
This publication highlights the importance of administering hepatitis B immune globulin and hepatitis B 
vaccine to infants of Hepatitis B positive mothers. The brochure included with this letter is for your 
patient, stressing the importance of vaccinating her child against HBV infection.   
 
Please remember two critical steps need to be taken for your patient:  
1. Send a copy of the original lab report indicating her HBsAg positive status to the birth hospital 
or center prior to delivery.  
2. Be sure the child receives Hepatitis B Immune Globulin (HBIG) and the first dose of hepatitis B 
Vaccine within 12 hours of birth.   
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
Your office may already have a policy in place to address HBV and birth transmission. We appreciate you 
reviewing this letter and making every effort to protect this child and stop the transmission of HBV at 
birth.   
 
Sincerely,  
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
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General Letter to Hospitals Prior to Birth 
 
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Regarding: Pregnant Mother with Hepatitis B 
 
Dear OB STAFF CONTACT:  
 
MOTHER’S NAME AND DOB is HBsAg positive and pregnant. Her estimated due date is DUE DATE. 
Currently, she plans to deliver at your hospital.   
 
Upon delivery, her child should receive the first dose of hepatitis B vaccine and HBIG (Hepatitis B 
Immune Globulin) within 12 hours of birth.   
 
Please complete the enclosed form “Perinatal Hepatitis B Hospital Report” regarding the administration 
of the hepatitis B vaccine birth dose and HBIG. Upon completion, please fax this form to YOUR FAX 
NUMBER. (FORM FOUND IN APPENDIX 2) 
 
For patients with no means of payment for HBIG and hepatitis B vaccine, please contact me.  The Iowa 
Department of Public Health will provide these important vaccinations without charge through the 
Vaccines for Children Program (VFC). However, IDPH does not maintain HBIG in inventory so advance 
planning is necessary to order this product from the manufacturer.     
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
 
 
Enc 
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General Letter to Baby’s 
Provider Prior to Birth 
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Regarding: Pregnant Mother with Hepatitis B 
 
Dear Health Care Provider:  
 
MOTHER’S NAME is HBsAg positive and pregnant. Her estimated due date is DUE DATE.  Currently she 
plans to deliver her baby at HOSPITAL NAME and bring her child to your clinic for well-child checkups 
and immunizations. This child should receive the first dose of hepatitis B vaccine and HBIG within 12 
hours of birth. Due to the exposure to hepatitis B at birth, it is very important this child receive the 2nd 
and 3rd doses of vaccine on time. 
 
According to guidance from CDC in the MMWR entitled “Prevention of Hepatitis B Virus Infection in the 
United States: Recommendations of the Advisory Committee on Immunization Practices” January 12, 
2018, infants born to HBsAg positive mothers should receive their second dose of hepatitis B vaccine at 
one-two months of age, followed by the third dose at six months of age. The final dose should not be 
administered prior to 24 weeks of age.    
 
Post-vaccination serologic testing is essential for these infants. Both HBsAg and quantitative anti-HBs 
lab tests should be performed after completion of the vaccine series at age 9-12 months (at least 1-2 
months following the final dose of vaccine and not before the age of 9 months). Without serologic 
testing the outcome of the preventive therapy is unknown and opportunities to revaccinate or treat are 
missed. I will be following up with your office regarding the test results.  
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
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General Letter to 
Baby’s Provider Post Birth 
ADD AGENCY LETTERHEAD 
 
Date 
 
Regarding: CHILD’S NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILD’S NAME birth date BIRTH DATE was born to an identified HBsAg positive mother NAME.  This child 
is planning to come to your clinic for well-child checkups and immunizations. This child received the first 
dose of hepatitis B vaccine and HBIG on DATE at HOSPITAL NAME. It is very important that this child 
receive 2nd and 3rd doses of vaccine on time. 
 
According to guidance from CDC in the MMWR entitled “Prevention of Hepatitis B Virus Infection in the 
United States: Recommendations of the Advisory Committee on Immunization Practices” January 12, 
2018,  infants born to HBsAg positive mothers should receive their second dose of hepatitis B vaccine at 
one-two months of age, followed by the third dose at six months of age. The final dose should not be 
administered prior to 24 weeks of age.    
 
Post-vaccination serologic testing is essential for these infants. Both HBsAg and quantitative anti-HBs 
lab tests should be performed after completion of the vaccine series at age 9-12 months (at least 1-2 
months following the final dose of vaccine and not before the age of 9 months). Without serologic 
testing the outcome of the preventive therapy is unknown and opportunities to revaccinate or treat are 
missed. Please complete the enclosed form and return to me at YOUR FAX NUMBER.  
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
Enc. 
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Letters to Providers Regarding Serology 
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Regarding: CHILD’S NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILD’S NAME was exposed to hepatitis B (HBV) at birth and is now due for post-vaccination serologic 
testing for HBV. Testing for immunity is essential for these infants. Both HBsAg and quantitative anti-
HBs lab tests should be performed after completion of the vaccine series at age 9-12 months.   
 
Without serologic testing the outcome of the preventive therapy is unknown and opportunities to 
revaccinate or treat are missed. Please complete the serologic testing results below or fax a copy of the 
child’s lab results to me at YOUR FAX NUMBER.  
 
Post vaccination serology drawn between 9-12 months of age (not before 9 months of age) 
    HBsAg Results ___________________________ 
    Quantitative anti-HBs Results ___________________________ 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
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Letter to Providers 
Regarding Overdue Serology 
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Regarding: CHILD’S NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILD’S NAME was exposed to hepatitis B at birth and is now past due for post-vaccination serologic 
testing for hepatitis B. Testing for immunity is essential for these infants. Both HBsAg and quantitative 
anti-HBs lab tests should be performed after completion of the vaccine series at age 9-12 months.  
 
This child is now older than 18 months and needs to be tested soon to determine immunity and if 
revaccination is needed.  
 
Without serologic testing the outcome of the preventive therapy is unknown and opportunities to 
revaccinate or treat are missed. Please complete the serologic testing results below or fax a copy of the 
child’s lab results to me at YOUR FAX NUMBER.  
Post vaccination serology drawn at ________months of age 
    HBsAg   Results ___________________________ 
    Quantitative anti-HBs Results ___________________________ 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program, please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
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Fax to Providers Regarding Serology 
 
ADD AGENCY LETTERHEAD 
 
DATE:  
 
FROM:   
 
TO:  
 
SUBJECT:  Hepatitis B Serology Information  
 
As part of the surveillance of reportable disease in Iowa, The Iowa Department of Public Health, 
Perinatal Hepatitis B Prevention Program needs the hepatitis B serology information for children born to 
Hepatitis B positive mothers (Iowa Administrative Code 641, Chapter 1). 
 
The child listed below was exposed to hepatitis B at birth and has completed the hepatitis B vaccine 
series. This infant is now due for the serology testing. The Centers for Disease Control and Prevention 
and the Iowa Department of Public Health recommend post-vaccination testing at 9-12 months of age. 
Without serologic testing the outcome of preventative therapy is unknown and opportunities to 
revaccinate or treat the child are missed.  
 
Child’s Name  _______________________________ DOB  _______________________ 
Mother’s Name  _____________________________ DOB  _______________________ 
 
Please fax the following information to YOUR NAME AND FAX: 
 
Test Results: 
Test Date:  __________________________________ 
Hepatitis B Surface Antigen (HBsAg)  __________________________________ 
 
Quantitative Hepatitis B Surface Antibody (anti-HBs)  ____________________________ 
 
If you have questions regarding the Iowa Perinatal Hepatitis B Prevention Program, please contact the 
State coordinator:  
Shelly Jensen, RN, BSN 
Iowa Department of Public Health, Immunization Program 
321 East 12th Street 
Des Moines, IA  50319 
P: (800) 831-6293 ext.2 
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Letter to Providers Regarding 
2nd Series of Immunizations  
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Regarding: CHILD’S NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILD’S NAME was exposed to hepatitis B (HBV) at birth. Subsequently, this child received hepatitis B 
vaccination and post-vaccination serologic testing. Unfortunately, according to the serology report, the 
child does not show immunity to hepatitis B and requires revaccination.   
 
The recommended approach is to administer a single dose of hepatitis B vaccine and complete post-
vaccination serologic testing 1-2 months later. Infants whose anti-HBs remains  
<10 mlU/mL following single dose re-vaccination should receive two additional doses of hepatitis B 
vaccine to complete the second series followed by post-vaccination testing 1-2 months after the final 
dose. 
 
Alternatively, based on clinical circumstances or family preference, these infants may instead be 
revaccinated with a complete second 3-dose series of vaccine (again at 0, 2 and 4 months) and re-test 
for both HBsAg and anti-HBs 1-2 months after the third dose of vaccine.  
 
If anti-HBs and HBsAg are still negative after 3 dose revaccination, the infant is considered a non-
responder to hepatitis B vaccine. 
 
Please complete the following information regarding hepatitis B vaccination series and post-vaccination 
serology for this infant: 
 
 HepB vaccine 4 - first dose in second vaccine series (0 months) Date given______________ 
  Faxed results to (YOUR FAX) 
 
Post vaccination serology drawn 1-2 months after 4th dose of vaccine  
Date of serology____________ 
 HBsAg Results ___________________________ 
 Quantitative anti-HBs Results ___________________________ 
  Faxed results to (YOUR FAX) 
 
 HepB vaccine 5 - if needed-second dose in second vaccine series (2 month) Date 
given_______________ 
  Faxed results to (YOUR FAX) 
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 HepB vaccine 6 -if needed-third dose in second vaccine series (4 months) Date 
given_______________ 
  Faxed results to (YOUR FAX) 
 
Post vaccination serology drawn 1-2 months after final dose of vaccine  
Date of serology ______________________ 
 HBsAg Results ___________________________ 
 Quantitative anti-HBs Results ___________________________ 
  Faxed results to (YOUR FAX) 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
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Letter to Providers 
Regarding Second Serology  
 
ADD AGENCY LETTERHEAD 
 
Date 
 
Regarding: CHILD’S NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILD’S NAME was exposed to hepatitis B at birth, received two complete series of hepatitis B vaccine, 
and is now due for the hepatitis B post-vaccination serologic testing for the second series. Both HBsAg 
and quantitative anti-HBs lab tests should be performed 1-2 months after completion of the second 
vaccine series.   
 
Please complete the serologic testing results below, or fax a copy of the child’s lab results to me at YOUR 
FAX NUMBER.  
 
Post vaccination serology drawn 1-2 months after the final dose of hepatitis B vaccine: 
 HBsAg Results ___________________________ 
 Quantitative anti-HBs Results ___________________________ 
 
If the child’s anti-HBs is <10mIU/mL after the second 3 dose series of vaccine, and is HBsAg negative, 
he/she should be considered susceptible to HBV infection. Data does not support a benefit of additional 
hepatitis B vaccine doses following two complete series. Educate the parents or guardians regarding 
precautions to prevent hepatitis B infection and the need to obtain HBIG prophylaxis if any known or 
probable parenteral exposure to HBsAg-positive blood (CDC Pink Book, 13th Edition). 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Shelly Jensen, RN, BSN at (800) 831-6293 ext. 2.   
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
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Letter to Postmaster 
Regarding Last Known Address  
ADD AGENCY LETTERHEAD 
 
Date 
 
US Postmaster 
Address of Main Post Office 
City of Question 
 
Dear Postmaster: 
 
YOUR AGENCY NAME has been working with the following individual, ADD MOM’S NAME, with a last 
known address of: 
LIST ADDRESS HERE 
 
We have been unable to contact this individual and would like your assistance in determining if they 
may have moved to a different address. If known, please provide our agency with an updated address 
for this individual in the section below.  
 
Forwarding Address: 
 
A stamped, self-addressed envelope has been provided for your convenience. Thank you for your time 
and assistance. Please feel free to contact me at YOUR NUMBER if you have any questions about this 
letter.  
 
Sincerely, 
STAFF NAME 
Perinatal Hepatitis B Prevention Program 
AGENCY NAME 
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Reference Materials and Resources 
Reference Materials 
Iowa Immunization Program 
Perinatal Hepatitis B Immunization Program 
https://idph.iowa.gov/immtb/immunization/perinatal-hepb 
Centers for Disease Control and Prevention https://www.cdc.gov/hepatitis/hbv/pdfs/HepBPerinatal-
ProtectWhenPregnant.pdf 
https://www.cdc.gov/hepatitis/hbv/patienteduhbv.htm 
https://www.cdc.gov/hepatitis/hbv/perinatalxmtn.htm 
Hep B Moms https://www.hepbmoms.org/ 
CDC Vaccines and Immunizations https://www.cdc.gov/vaccines/index.html  
Immunization Action Coalition http://www.immunize.org 
Hepatitis B Foundation http://www.hepb.org/ 
Parents of Kids with Infectious Disease http://www.pkids.org/ 
Hepatitis B Vaccination Information for Health Care 
Providers 
https://www.cdc.gov/vaccines/vpd/hepb/hcp/ 
Resources 
IDPH Brochures (Available free of charge) https://idph.iowa.gov/immtb/immunization/order-form 
Hepatitis B and Mom’s To Be Brochures http://med.stanford.edu/content/dam/sm/liver/documents
/resources/English.pdf 
VIS Statements (Multiple languages available) http://www.immunize.org/vis/index.htm#hepatitisb 
Hep B Moms https://www.hepbmoms.org/brochures 
Frequently Asked Questions About Hepatitis B:  http://www.immunize.org/catg.d/p4090.pdf 
Guidelines for Standing Orders Hospital:   http://www.immunize.org/catg.d/p2130.pdf 
Sample Standing Orders Children and Teens:  http://www.immunize.org/catg.d/p3076a.pdf 
CDC Pink Book Chapter on Hepatitis B:  http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/h
epb.pdf 
Iowa Administrative Code Chapter 641.1:   https://www.legis.iowa.gov/docs/ACO/chapter/01-21-
2015.641.1.pdf 
MMWR, Vol. 67/No.1/January 12, 2018 
Prevention of Hepatitis B Virus Infection in the United 
States: Recommendations of the Advisory Committee on 
Immunization Practices.  
https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-
H.pdf 
IDPH EPI Manual – Hepatitis B Chapter:  https://wiki.idph.iowa.gov/epimanual/Home/CategoryID/84 
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Appendix 1 
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Appendix 2  
